Skip to main content

Power3, Biosite to Develop Protein Biomarker-based Diagnostics

NEW YORK, July 12 (GenomeWeb News) - Proteomic tool shop Power3 Medical Products will give Biosite access to certain of its protein biomarker antibody targets and intellectual property as part of an alliance to evaluate and develop diagnostic tests, the companies said today.

Terms of the agreement call for Biosite to develop and commercialize all potential immunodiagnostic tests based on the Power3 biomarker antibody targets it licensed from the company.

Power3's IP portfolio includes pending patents, provisional patent applications, and research and license agreements with medical research institutions in the areas of cancer, drug resistance, neurodegenerative disease, and metabolic syndrome, the company said.

The financial terms of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.